1-5 of 5
Milan Zdravkovic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Bernard Zinman, MD, John Gerich, MD, John B. Buse, MD, PHD, Andrew Lewin, MD, Sherwyn Schwartz, MD, Philip Raskin, MD, Paula M. Hale, PHD, Milan Zdravkovic, PHD, Lawrence Blonde, MD, the LEAD-4 Study Investigators
Journal: Diabetes Care
Diabetes Care 2009;32(7):1224–1230
https://doi.org/10.2337/dc08-2124
Published: 16 March 2009
View article titled, Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Open the PDF for Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

Michael Nauck, MD, PHD, Anders Frid, MD, Kjeld Hermansen, MD, Nalini S. Shah, MD, Tsvetalina Tankova, MD, Ismail H. Mitha, MD, Milan Zdravkovic, MD, PHD, Maria Düring, PHD, David R. Matthews, MD, for the LEAD-2 Study Group
Journal: Diabetes Care
Diabetes Care 2009;32(1):84–90
https://doi.org/10.2337/dc08-1355
Published: 01 January 2009
View article titled, Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: <subtitle>The LEAD (Liraglutide Effect and Action in Diabetes)-2 study</subtitle>
Open the PDF for Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: <subtitle>The LEAD (Liraglutide Effect and Action in Diabetes)-2 study</subtitle> in another window
Includes: Supplementary data
Journal Articles

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, MD, DMSC, Milan Zdravkovic, MD, PHD, Tu Le-Thi, MSC, Thure Krarup, MD, DMSC, Ole Schmitz, MD, DMSC, Jean-Pierre Courrèges, MD, Robert Verhoeven, MD, Ingrid Bugánová, MD, Sten Madsbad, MD, DMSC
Journal: Diabetes Care
Diabetes Care 2007;30(6):1608–1610
https://doi.org/10.2337/dc06-2593
Published: 01 June 2007
View article titled, Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Open the PDF for Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes in another window
Journal Articles

A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir

Johannes Plank, MD, Manfred Bodenlenz, PHD, Frank Sinner, PHD, Christoph Magnes, PHD, Evelyn Görzer, MD, Werner Regittnig, PHD, Lars A. Endahl, MSC, Eberhard Draeger, MD, Milan Zdravkovic, MD, Thomas R. Pieber, MD
Journal: Diabetes Care
Diabetes Care 2005;28(5):1107–1112
https://doi.org/10.2337/diacare.28.5.1107
Published: 01 May 2005
View article titled, A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir
Open the PDF for A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir in another window
Journal Articles

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

Bodil Elbrønd, MD, Grethe Jakobsen, MSC, Søren Larsen, MSC, Henrik Agersø, PHD, Lisbeth Bjerring Jensen, PHD, Paul Rolan, MD, Jeppe Sturis, PHD, Vibeke Hatorp, MSC, Milan Zdravkovic, PHD
Journal: Diabetes Care
Diabetes Care 2002;25(8):1398–1404
https://doi.org/10.2337/diacare.25.8.1398
Published: 01 August 2002
View article titled, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects
Open the PDF for Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects in another window